eFT508
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Castrate-resistant Prostate Cancer (CRPC)
Conditions
Castrate-resistant Prostate Cancer (CRPC)
Trial Timeline
Nov 27, 2018 → Apr 27, 2020
NCT ID
NCT03690141About eFT508
eFT508 is a phase 2 stage product being developed by eFFECTOR Therapeutics for Castrate-resistant Prostate Cancer (CRPC). The current trial status is terminated. This product is registered under clinical trial identifier NCT03690141. Target conditions include Castrate-resistant Prostate Cancer (CRPC).
What happened to similar drugs?
0 of 2 similar drugs in Castrate-resistant Prostate Cancer (CRPC) were approved
Approved (0) Terminated (1) Active (1)
❌custirsen sodium + isotonic, 0.9% sodium chloride + docetaxel + cabazitaxel + prednisoneAchieve Life SciencesPhase 3
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03690141 | Phase 2 | Terminated |
| NCT03318562 | Phase 2 | Terminated |
| NCT02605083 | Phase 1/2 | Terminated |
Competing Products
9 competing products in Castrate-resistant Prostate Cancer (CRPC)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD4635 + Durvalumab + Cabazitaxel | AstraZeneca | Phase 2 | 35 |
| Intermittent dosing of AZD5363 + Intermittent dosing of AZD5363 + Intermittent dosing of AZD5363 | AstraZeneca | Phase 1 | 29 |
| Part A: AZD8186 monotherapy + Part B: AZD8186 monotherapy + Part C1: Abiraterone acetate combination with AZD8186 + Part D1: AZD2014 combination with AZD8186 + Part D2 AZD2014 combination with AZD8186 + Part C2: Abiraterone acetate combination with AZD8186 | AstraZeneca | Phase 1 | 29 |
| BEZ235 + Prednisone + Abiraterone acetate | Novartis | Phase 1/2 | 24 |
| Atezolizumab + Radium-223 Dichloride | Roche | Phase 1 | 29 |
| Denosumab | Amgen | Phase 3 | 40 |
| Alobresib + Enzalutamide | Gilead Sciences | Phase 1/2 | 24 |
| ISIS EIF4E Rx + ISIS EIF4E Rx + ISIS EIF4E Rx + Prednisone + Docetaxel | Ionis Pharmaceuticals | Phase 1/2 | 29 |
| custirsen sodium + isotonic, 0.9% sodium chloride + docetaxel + cabazitaxel + prednisone | Achieve Life Sciences | Phase 3 | 22 |